Deep Medicine Acquisition Corp.
Deep Medicine Acquisition Corp. (DMAQ) Revenue
Annual & quarterly revenue history · segment & region breakdown
DMAQ · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsDeep Medicine Acquisition Corp. trailing twelve-month (TTM) revenue is $0.02B, a decrease of 13.63% year-over-year from $0.02B in FY2026.
Revenue trend
2026 – 2022 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2026-03-31 | $0.02B | -$0.00B | -13.63% |
| 2025-03-31 | $0.02B | +$0.02B | — |
| 2023-03-31 | $0.00B | +$0.00B | — |
| 2022-03-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Deep Medicine Acquisition Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Deep Medicine Acquisition Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Deep Medicine Acquisition Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DMAQ revenue · 4 questionsDMAQ's trailing twelve-month (TTM) revenue is $0.02B. That is a decrease of 13.63% year-over-year from $0.02B in FY2026.
▸ Source: FMP · Deep Medicine Acquisition Corp. SEC filings · GAAP · Deep Medicine Acquisition Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026